2
The Food and Drug Administration says it would begin phasing out animal testing requirements for antibody therapies and other drugs and move toward AI-based models and other tools it deems “human-relevant.” Axios: The FDA said it would launch a pilot program over the next year allowing select developers of monoclonal antibodies to use a primarily non-animal-based testing strategy. Commissioner Marty Makary in a statement said the shift would improve drug safety, lower research and development costs and address ethical concerns about animal experimentation.